Rivaroxaban in Peripheral Artery Disease after RevascularizationMarc P. Bonaca, William R. Hiatt|New England Journal of Medicine|2020Cited by 966
Ticagrelor versus Clopidogrel in Symptomatic Peripheral Artery DiseaseWilliam R. Hiatt, Manesh R. Patel, F. Gerry R. Fowkes et al.|New England Journal of Medicine|2016Cited by 628
Incidence and Factors Associated With Major Amputation in Patients With Peripheral Artery DiseaseChandler A. Long, Mark R. Nehler, Hillary Mulder et al.|Circulation Cardiovascular Quality and Outcomes|2020Cited by 43
The Flavr Savr Tomato, an Early Example of RNAi TechnologyElysia K. Krieger, Rick Sanders, Edwards Allen et al.|HortScience|2008Cited by 32
Risk assessment in drug development for symptomatic indications: A framework for the prospective exclusion of unacceptable cardiovascular riskEric P. Brass, William R. Hiatt, Robert A. Lewis et al.|Clinical Pharmacology & Therapeutics|2006Cited by 22